Modified Folfox6 With Or Without Radiation Versus Fluorouracil And Leucovorin With Radiation In Neoadjuvant Treatment Of Locally Advanced Rectal Cancer: Initial Results Of The Chinese Fowarc Multicenter, Open-Label, Randomized Three-Arm Phase Iii Trial
Yanhong Deng,Pan Chi,Ping Lan,Lei Wang,Weiqing Chen,Long Cui,Daoda Chen,Jie Cao,Hongbo Wei,Xiang Peng,Zonghai Huang,Guanfu Cai,Ren Zhao,Zhongcheng Huang,Lin Xu,Hongfeng Zhou,Yisheng Wei,Hao Zhang,Jian Zheng,Yan Huang,Zhiyang Zhou,Yue Cai,Liang Kang,Meijin Huang,Junsheng Peng,Donglin Ren,Jianping Wang
DOI: https://doi.org/10.1200/JCO.2016.66.6198
IF: 45.3
2016-01-01
Journal of Clinical Oncology
Abstract:PurposeTotal mesorectal excision with fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy is a standard treatment of locally advanced rectal cancer. This study investigated the addition of oxaliplatin with and without preoperative radiotherapy.MethodsIn this multicenter, open-label, phase III trial, we randomly assigned (1:1:1) Chinese adults (age 18 to 75 years) with locally advanced stage II/III rectal cancer to three treatments: five 2-week cycles of infusional fluorouracil (leucovorin 400 mg/m(2), fluorouracil 400 mg/m(2), and fluorouracil 2.4 g/m(2) over 48 h) plus radiotherapy (46.0 to 50.4 Gy delivered in 23 to 25 fractions during cycles 2 through 4) followed by surgery and seven cycles of infusional fluorouracil, the same treatment plus intravenous oxaliplatin 85 mg/m(2) on day 1 of each cycle (modified FOLFOX6 [mFOLFOX6]), or four to six cycles of mFOLFOX6 followed by surgery and six to eight cycles of mFOLFOX6. Random assignment was performed by using computer-generated block randomization codes. The primary end point was 3-year disease-free survival. Secondary end points of histopathologic response and toxicity are reported.ResultsA total of 495 patients were enrolled from June 2010 to February 2015; 475 were evaluable (fluorouracil-radiotherapy, n = 155; mFOLFOX6-radiotherapy, n = 157; mFOLFOX6, n = 163). In the fluorouracil-radiotherapy, mFOLFOX6-radiotherapy, and mFOLFOX6 groups, the rate of pathologic complete response (pCR) was 14.0%, 27.5%, and 6.6%, and downstaging (ypStage 0 to 1) was achieved by 37.1%, 56.4%, and 35.5% of patients, respectively. Higher toxicity and more postoperative complications were observed in patients who received radiotherapy.ConclusionmFOLFOX6-based preoperative chemoradiotherapy results in a higher pCR rate than fluorouracil-based treatment. Perioperative mFOLFOX6 alone had inferior results and a lower pCR rate than chemoradiotherapy but led to a similar downstaging rate as fluorouracil-radiotherapy, with less toxicity and fewer postoperative complications. (C) 2016 by American Society of Clinical Oncology